comparemela.com
Home
Live Updates
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab ... : comparemela.com
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab ...
Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive
Related Keywords
Denmark ,
Japan ,
Copenhagen ,
Køavn ,
United States ,
Chicago ,
Illinois ,
Germany ,
America ,
American ,
Asia Pacific ,
Andrew Carlsen ,
Fosun Pharma ,
David Freundel ,
Exchange Commission ,
Linkedin ,
Pfizer ,
Roche Group ,
Genentech ,
American Cancer Society ,
American Society Of Clinical Oncology ,
Clinical Oncology ,
Annual Meeting ,
Non Small Cell Lung Cancer ,
North America ,
Media Release ,
Annual Report ,
Y Shaped Genmab ,
New Technologies ,
Private Securities Litigation Reform Act ,
American Cancer ,
Non Small Cell Lung ,
Accessed May ,
Lung Cancer ,
Non Small Cell ,
comparemela.com © 2020. All Rights Reserved.